- Home
- SILC vs RVPHW Comparison
SILC vs RVPHW Comparison
Compare SILC & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- RVPHW
- Stock Information
- Founded
- SILC 1987
- RVPHW 2018
- Country
- SILC Israel
- RVPHW United States
- Employees
- SILC N/A
- RVPHW 14
- Industry
- SILC Computer Manufacturing
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- RVPHW Health Care
- Exchange
- SILC Nasdaq
- RVPHW Nasdaq
- Market Cap
- SILC 85.1M
- RVPHW N/A
- IPO Year
- SILC 1994
- RVPHW N/A
- Fundamental
- Price
- SILC $15.66
- RVPHW $0.04
- Analyst Decision
- SILC Hold
- RVPHW
- Analyst Count
- SILC 2
- RVPHW 0
- Target Price
- SILC N/A
- RVPHW N/A
- AVG Volume (30 Days)
- SILC 12.6K
- RVPHW 22.4K
- Earning Date
- SILC 07-31-2025
- RVPHW 03-14-2025
- Dividend Yield
- SILC N/A
- RVPHW N/A
- EPS Growth
- SILC N/A
- RVPHW N/A
- EPS
- SILC N/A
- RVPHW N/A
- Revenue
- SILC $58,134,000.00
- RVPHW N/A
- Revenue This Year
- SILC $6.26
- RVPHW N/A
- Revenue Next Year
- SILC $19.14
- RVPHW N/A
- P/E Ratio
- SILC N/A
- RVPHW N/A
- Revenue Growth
- SILC N/A
- RVPHW N/A
- 52 Week Low
- SILC $11.35
- RVPHW $0.13
- 52 Week High
- SILC $18.24
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- SILC 56.07
- RVPHW N/A
- Support Level
- SILC $14.93
- RVPHW N/A
- Resistance Level
- SILC $15.97
- RVPHW N/A
- Average True Range (ATR)
- SILC 0.57
- RVPHW 0.00
- MACD
- SILC 0.01
- RVPHW 0.00
- Stochastic Oscillator
- SILC 68.22
- RVPHW 0.00
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.